Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Quality of Life and Sexual Functioning After Vulvar Reconstruction With the Lotus Petal Flap.

Hellinga J, Te Grootenhuis NC, Werker PMN, de Bock GH, van der Zee AGJ, Oonk MHM, Stenekes MW.

Int J Gynecol Cancer. 2018 Aug 29. doi: 10.1097/IGC.0000000000001340. [Epub ahead of print]

PMID:
30157166
2.

Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer.

Verlaat W, Van Leeuwen RW, Novianti PW, Schuuring E, Meijer CJLM, Van Der Zee AGJ, Snijders PJF, Heideman DAM, Steenbergen RDM, Wisman GBA.

Epigenetics. 2018 Aug 24:1-10. doi: 10.1080/15592294.2018.1507197. [Epub ahead of print]

PMID:
30079796
3.

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S.

Biochim Biophys Acta Rev Cancer. 2018 Jul 16. pii: S0304-419X(18)30091-X. doi: 10.1016/j.bbcan.2018.07.005. [Epub ahead of print] Review.

PMID:
30025943
4.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Maldonado L, Brait M, Izumchenko E, Begum S, Chatterjee A, Sen T, Loyo M, Barbosa A, Poeta ML, Makarev E, Zhavoronkov A, Fazio VM, Angioli R, Rabitti C, Ongenaert M, Van Criekinge W, Noordhuis MG, de Graeff P, Wisman GBA, van der Zee AGJ, Hoque MO.

Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.

PMID:
29964205
5.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]

6.

Proteomic alterations in early stage cervical cancer.

Güzel C, Govorukhina NI, Wisman GBA, Stingl C, Dekker LJM, Klip HG, Hollema H, Guryev V, Horvatovich PL, van der Zee AGJ, Bischoff R, Luider TM.

Oncotarget. 2018 Apr 6;9(26):18128-18147. doi: 10.18632/oncotarget.24773. eCollection 2018 Apr 6.

7.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
8.

Surgical Treatment of Early-Stage Cervical Cancer: A Multi-Institution Experience in 2124 Cases in The Netherlands Over a 30-Year Period.

Derks M, van der Velden J, de Kroon CD, Nijman HW, van Lonkhuijzen LRCW, van der Zee AGJ, Zwinderman AH, Kenter GG.

Int J Gynecol Cancer. 2018 May;28(4):757-763. doi: 10.1097/IGC.0000000000001228.

PMID:
29595758
9.

Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review.

Te Grootenhuis NC, Pouwer AW, de Bock GH, Hollema H, Bulten J, van der Zee AGJ, de Hullu JA, Oonk MHM.

Gynecol Oncol. 2018 Mar;148(3):622-631. doi: 10.1016/j.ygyno.2017.11.006. Epub 2017 Nov 12. Review.

PMID:
29137809
10.

Comparison of Targeted Mass Spectrometry Techniques with an Immunoassay: A Case Study for HSP90α.

Güzel C, Govorukhina NI, Stingl C, Dekker LJM, Boichenko A, van der Zee AGJ, Bischoff RPH, Luider TM.

Proteomics Clin Appl. 2018 Jan;12(1). doi: 10.1002/prca.201700107. Epub 2017 Oct 30.

PMID:
28975736
11.

IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.

Liefers-Visser JAL, Meijering RAM, Reyners AKL, van der Zee AGJ, de Jong S.

Cancer Treat Rev. 2017 Nov;60:90-99. doi: 10.1016/j.ctrv.2017.08.012. Epub 2017 Sep 8. Review.

12.

Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Oct;84:370. doi: 10.1016/j.ejca.2017.08.003. Epub 2017 Aug 23. No abstract available.

PMID:
28844347
13.

Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.

Corvigno S, Frödin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirström K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, Johansson M, Dahlstrand H, Mezheyeuski A, Östman A.

J Pathol Clin Res. 2017 Jul 24;3(3):214-224. doi: 10.1002/cjp2.74. eCollection 2017 Jul.

14.

Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study.

Pouwer AW, Hinten F, van der Velden J, Smolders RGV, Slangen BFM, Zijlmans HJMAA, IntHout J, van der Zee AGJ, Boll D, Gaarenstroom KN, Arts HJ, de Hullu JA.

Gynecol Oncol. 2017 Sep;146(3):580-587. doi: 10.1016/j.ygyno.2017.06.031. Epub 2017 Jul 4.

PMID:
28687171
15.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

16.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer.

Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F, Mahner S, Mahantshetty U, Mirza M, Petersen C, Querleu D, Regauer S, Rob L, Rouzier R, Ulrikh E, van der Velden J, Vergote I, Woelber L, van der Zee AGJ.

Int J Gynecol Cancer. 2017 May;27(4):832-837. doi: 10.1097/IGC.0000000000000975.

PMID:
28441255
17.

Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Jun;78:82-90. doi: 10.1016/j.ejca.2017.03.010. Epub 2017 Apr 14. Erratum in: Eur J Cancer. 2017 Oct;84:370.

PMID:
28415003
18.

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.

Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA.

PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.

19.
20.

Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Wang R, van Leeuwen RW, Boers A, Klip HG, de Meyer T, Steenbergen RD, van Criekinge W, van der Zee AG, Schuuring E, Wisman GB.

Oncotarget. 2016 Dec 6;7(49):80735-80750. doi: 10.18632/oncotarget.12598.

21.

Molecular imaging in ovarian cancer.

Reyners AK, Broekman KE, Glaudemans AW, Brouwers AH, Arts HJ, van der Zee AG, de Vries EG, Jalving M.

Ann Oncol. 2016 Apr;27 Suppl 1:i23-i29. doi: 10.1093/annonc/mdw091. Review.

PMID:
27141066
22.

Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.

Eggink FA, Mom CH, Kruitwagen RF, Reyners AK, Van Driel WJ, Massuger LF, Niemeijer GC, Van der Zee AG, Van der Aa MA, Nijman HW.

Gynecol Oncol. 2016 Jun;141(3):524-530. doi: 10.1016/j.ygyno.2016.04.012. Epub 2016 Apr 23.

PMID:
27090157
23.

The Risk of Contralateral Nonsentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Oonk MH, van der Zee AG.

Ann Surg Oncol. 2016 Aug;23(8):2383-4. doi: 10.1245/s10434-016-5157-8. Epub 2016 Mar 30. No abstract available.

PMID:
27027311
24.

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, Schuuring E, Wisman GBA.

Clin Epigenetics. 2016 Mar 9;8:29. doi: 10.1186/s13148-016-0196-3. eCollection 2016.

25.

Identification of Analytical Factors Affecting Complex Proteomics Profiles Acquired in a Factorial Design Study with Analysis of Variance: Simultaneous Component Analysis.

Mitra V, Govorukhina N, Zwanenburg G, Hoefsloot H, Westra I, Smilde A, Reijmers T, van der Zee AG, Suits F, Bischoff R, Horvatovich P.

Anal Chem. 2016 Apr 19;88(8):4229-38. doi: 10.1021/acs.analchem.5b03483. Epub 2016 Mar 28.

PMID:
26959230
26.

Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival.

Corvigno S, Wisman GB, Mezheyeuski A, van der Zee AG, Nijman HW, Åvall-Lundqvist E, Östman A, Dahlstrand H.

Oncotarget. 2016 Apr 5;7(14):18573-84. doi: 10.18632/oncotarget.7613.

27.

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.

Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26. Review.

PMID:
26830315
28.

Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible.

van Doorn HC, van Beekhuizen HJ, Gaarenstroom KN, van der Velden J, van der Zee AG, Oonk MH, de Hullu JA.

Gynecol Oncol. 2016 Mar;140(3):415-9. doi: 10.1016/j.ygyno.2016.01.013. Epub 2016 Jan 12.

PMID:
26797295
29.

Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Mol Ther. 2016 Mar;24(3):536-47. doi: 10.1038/mt.2015.226. Epub 2015 Dec 21.

30.

Breaking the DNA damage response to improve cervical cancer treatment.

Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA.

Cancer Treat Rev. 2016 Jan;42:30-40. doi: 10.1016/j.ctrv.2015.11.008. Epub 2015 Nov 24. Review.

PMID:
26643553
31.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

32.

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods.

Alkema NG, Tomar T, Duiker EW, Jan Meersma G, Klip H, van der Zee AG, Wisman GB, de Jong S.

Sci Rep. 2015 Oct 6;5:14495. doi: 10.1038/srep14495.

33.

Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

Te Grootenhuis NC, van der Zee AG, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, Baldwin PJ, Gaarenstroom KN, van Dorst EB, Trum JW, Slangen BF, Runnebaum IB, Tamussino K, Hermans RH, Provencher DM, de Bock GH, de Hullu JA, Oonk MH.

Gynecol Oncol. 2016 Jan;140(1):8-14. doi: 10.1016/j.ygyno.2015.09.077. Epub 2015 Sep 30.

PMID:
26428940
34.

Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.

de Boer E, Crane LM, van Oosten M, van der Vegt B, van der Sluis T, Kooijman P, Low PS, van der Zee AG, Arts HJ, van Dam GM, Bart J.

PLoS One. 2015 Aug 6;10(8):e0135012. doi: 10.1371/journal.pone.0135012. eCollection 2015.

35.

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.

du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT).

Int J Gynecol Cancer. 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.0000000000000478.

PMID:
26067859
36.

Sentinel node biopsy in vulvar cancer: Implications for staging.

Oonk MH, Hollema H, van der Zee AG.

Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):812-21. doi: 10.1016/j.bpobgyn.2015.03.007. Epub 2015 Mar 28. Review.

PMID:
25962357
37.

Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.

Huisman C, van der Wijst MG, Falahi F, Overkamp J, Karsten G, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Epigenetics. 2015;10(5):384-96. doi: 10.1080/15592294.2015.1034415. Epub 2015 Apr 1.

38.

Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.

Boers A, Wang R, Slagter-Menkema L, van Hemel BM, Ghyssaert H, van der Zee AG, Wisman GB, Schuuring E.

J Clin Microbiol. 2014 Dec;52(12):4391-3. doi: 10.1128/JCM.02716-14. Epub 2014 Oct 8.

39.

A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer.

Boichenko AP, Govorukhina N, Klip HG, van der Zee AG, Güzel C, Luider TM, Bischoff R.

J Proteome Res. 2014 Nov 7;13(11):4995-5007. doi: 10.1021/pr500601w. Epub 2014 Sep 29.

PMID:
25232869
40.

New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers.

Ferreira AM, Tuominen I, Sousa S, Gerbens F, van Dijk-Bos K, Osinga J, Kooi KA, Sanjabi B, Esendam C, Oliveira C, Terpstra P, Hardonk M, van der Sluis T, Zazula M, Stachura J, van der Zee AG, Hollema H, Sijmons RH, Aaltonen LA, Seruca R, Hofstra RM, Westers H.

Hum Mutat. 2014 Dec;35(12):1514-23. doi: 10.1002/humu.22700.

PMID:
25231886
41.

High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors.

Ferreira AM, Tuominen I, van Dijk-Bos K, Sanjabi B, van der Sluis T, van der Zee AG, Hollema H, Zazula M, Sijmons RH, Aaltonen LA, Westers H, Hofstra RM.

Hum Mutat. 2014 Dec;35(12):1442-5. doi: 10.1002/humu.22686.

PMID:
25196364
42.

Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.

Boers A, Slagter-Menkema L, van Hemel BM, Belinson JL, Ruitenbeek T, Buikema HJ, Klip H, Ghyssaert H, van der Zee AG, de Bock GH, Wisman GB, Schuuring E.

PLoS One. 2014 Jul 22;9(7):e101930. doi: 10.1371/journal.pone.0101930. eCollection 2014.

43.

DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB.

Br J Cancer. 2014 Sep 9;111(6):1095-101. doi: 10.1038/bjc.2014.392. Epub 2014 Jul 17.

44.

Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer.

Boers A, Arts HJ, Klip H, Nijhuis ER, Pras E, Hollema H, Wisman GB, Nijman HW, Mourits MJ, Reyners AK, de Bock GH, Thomas G, van der Zee AG.

Int J Gynecol Cancer. 2014 Sep;24(7):1276-85. doi: 10.1097/IGC.0000000000000171.

PMID:
24987914
45.

No increased systemic fibrinolysis in women with heavy menstrual bleeding.

Wiewel-Verschueren S, Knol HM, Lisman T, Bogchelman DH, Kluin-Nelemans JC, van der Zee AG, Mulder AB, Meijer K.

J Thromb Haemost. 2014 Sep;12(9):1488-93. doi: 10.1111/jth.12645. Epub 2014 Jul 23.

46.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
47.

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.

Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG, de Jong S.

Br J Cancer. 2013 Nov 12;109(10):2685-95. doi: 10.1038/bjc.2013.636. Epub 2013 Oct 17.

48.

Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, Marchionni L, de Graeff P, van der Zee AG, Wisman GB, Sidransky D, Hoque MO.

PLoS One. 2013 Sep 27;8(9):e70878. doi: 10.1371/journal.pone.0070878. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/ccd51e37-fdf3-466e-b79f-2c390df9ab28. PLoS One. 2013;8(10). doi:10.1371/annotation/5d2e13d4-cb4e-44b1-a836-dff9b4144b5b. Noordhuis, Maartje [corrected to Noordhuis, Maartje G].

49.

Multidimensional separation of tryptic peptides from human serum proteins using reversed-phase, strong cation exchange, weak anion exchange, and fused-core fluorinated stationary phases.

Boichenko AP, Govorukhina N, van der Zee AG, Bischoff R.

J Sep Sci. 2013 Nov;36(21-22):3463-70. doi: 10.1002/jssc.201300750. Epub 2013 Sep 13.

PMID:
24039020
50.

Application of sentinel nodes in gynaecological cancer therapy.

Oonk MH, van der Zee AG.

EJC Suppl. 2013 Sep;11(2):287-8. doi: 10.1016/j.ejcsup.2013.07.054. Review. No abstract available.

Supplemental Content

Loading ...
Support Center